Kintara Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Academic Collaborations
    • Advisors
  • Pipeline
    • Overview
    • VAL-083
    • REM-001
  • Clinical Trials
  • News & Media
    • Press Releases
    • Publications and Abstracts
    • Presentations
    • Events
  • Investors
    • Overview
    • Analyst Coverage
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Press Releases

News & Media

News & Media

  • Press Releases
  • Publications and Abstracts
  • Presentations
  • Events

DelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of Directors

Jun 25, 2018

DelMar Appoints Saiid Zarrabian to Full-Time President and CEO

May 22, 2018

DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results

May 17, 2018

DelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM

Apr 17, 2018

DelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer Research

Apr 16, 2018

DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2018 Financial Results

Feb 14, 2018

DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma

Dec 26, 2017

DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting

Nov 21, 2017

DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial Results

Nov 13, 2017

DelMar Pharmaceuticals Appoints Saiid Zarrabian as Interim Chief Executive Officer

Nov 7, 2017
    • 1...
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • ...27
    © 2021 Kintara Therapeutics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Legal Information